Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Pratt

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
Haematologica|July 21, 2018
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VIPhillip L R Nicolson, Craig E Hughes, Stephanie Watson, et al.
British Journal of Haematology|December 17, 2011
Defining the prognosis of early stage chronic lymphocytic leukaemia patientsChris Pepper, Aneela Majid, Thet Thet Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphomaVéronique Leblond, Steve Johnson, Sylvie Chevret, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
Journal of Hematology & Oncology|January 10, 2022
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemiaHelen Parry, Graham McIlroy, Rachel Bruton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
Blood|May 13, 2017
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional statusAngelo Agathanggelou, Edward Smith, Nicholas J Davies, et al.
British Journal of Haematology|February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysisAnnabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.
Blood|January 9, 2024
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosisJoshua Bomsztyk, Sriram Ravichandran, Hannah V Giles, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Haematologica|July 21, 2018
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VIPhillip L R Nicolson, Craig E Hughes, Stephanie Watson, et al.
British Journal of Haematology|December 17, 2011
Defining the prognosis of early stage chronic lymphocytic leukaemia patientsChris Pepper, Aneela Majid, Thet Thet Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphomaVéronique Leblond, Steve Johnson, Sylvie Chevret, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
Journal of Hematology & Oncology|January 10, 2022
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemiaHelen Parry, Graham McIlroy, Rachel Bruton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
Blood|May 13, 2017
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional statusAngelo Agathanggelou, Edward Smith, Nicholas J Davies, et al.
British Journal of Haematology|February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysisAnnabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.
Blood|January 9, 2024
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosisJoshua Bomsztyk, Sriram Ravichandran, Hannah V Giles, et al.
Pageof 14